Search

Displaying results 501 - 510 of 9347 in total
  1. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    may be exposed to the virus. … SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2).

  2. Drug

    Hexobarbital

    go.drugbank.com/drugs/DB01355
    Experimental

    A barbiturate that is effective as a hypnotic and sedative.

  3. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Dermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427]. … Dermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia.

  4. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

    Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linker
  5. Drug

    EN001

    go.drugbank.com/drugs/DB33920
    Experimental

    EN001 is under investigation in clinical trial NCT07808905 (Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia (Phase 1: Open-label, Dose-escalation, Single-center ; Phase2: Randomized

  6. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    [L49469] This approval was based on positive results demonstrated in the open-label, single-arm Phase 3 BENEGENE-2 study, where the annualized bleeding rate (ABR) was observed to be 1.3 for the 12 months … from week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period.

  7. Drug

    Ferrous fumarate

    go.drugbank.com/drugs/DB14491
    ApprovedInvestigational

    Used in treatment of iron deficiency anemia.

    Mixtures: TL-Icon, TL-Select
  8. Drug

    Pegsitacianine

    go.drugbank.com/drugs/DB19098
    Investigational

    Pegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence … Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)).

  9. Drug

    Muplestim

    go.drugbank.com/drugs/DB12431
    Investigational

    Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL

  10. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.